Pieris Pharmaceuticals Company Profile (NASDAQ:PIRS)

Analyst Ratings

Consensus Ratings for Pieris Pharmaceuticals (NASDAQ:PIRS) (?)
Ratings Breakdown: 3 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $9.50 (439.77% upside)

Analysts' Ratings History for Pieris Pharmaceuticals (NASDAQ:PIRS)
Show:
DateFirmActionRatingPrice TargetActions
3/24/2016Roth CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$10.00 -> $9.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/8/2015Oppenheimer Holdings Inc.Reiterated RatingBuy$8.00 -> $10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/30/2014 forward)

Earnings

Earnings History for Pieris Pharmaceuticals (NASDAQ:PIRS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/10/2016        
5/12/2016Q116($0.12)($0.10)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/23/2016Q415($0.12)($0.07)$3.27 million$2.14 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2015Q315($0.11)($0.10)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2015Q215($0.14)($0.12)$160.24 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Pieris Pharmaceuticals (NASDAQ:PIRS)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161$0.03$0.03$0.03
Q2 20162($0.16)($0.12)($0.14)
Q3 20162($0.14)($0.12)($0.13)
Q4 20162($0.14)($0.12)($0.13)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Pieris Pharmaceuticals (NASDAQ:PIRS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Pieris Pharmaceuticals (NASDAQ:PIRS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/14/2016Louis MatisSVPBuy10,000$1.70$17,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/13/2016Darlene M Deptula-HicksCFOBuy5,000$1.66$8,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/13/2016Stephen S YoderCEOBuy6,000$1.68$10,080.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Pieris Pharmaceuticals (NASDAQ:PIRS)
DateHeadline
07/27/16 06:13 PMPieris Pharmaceuticals Appoints Julian Adams, Ph.D., to Its Board of Directors - Marketwired (press release)
07/26/16 08:23 AMPIERIS PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and -
07/22/16 05:42 PMChecking in on Stock Volatility for: Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) - Engelwood Daily
07/22/16 05:42 PMPieris Pharmaceuticals Inc (NASDAQ:PIRS): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/22/16 05:42 PMPieris Pharmaceuticals Incorporated (NASDAQ:PIRS) Shorted Shares Increased 43.71% After Market Selling - Consumer Eagle
07/21/16 08:43 AMPieris Pharmaceuticals Inc Stock Technicals at Critical Inflection Point - CML News
07/21/16 08:43 AMEquity Roundup: Stock Performance Focus on Pieris Pharmaceuticals Inc (NASDAQ:PIRS) - Press Telegraph
07/20/16 08:41 AMStock Focus: Following Analyst Expectations on Shares of Pieris Pharmaceuticals Inc (NASDAQ:PIRS) - TGP
07/20/16 08:41 AMEarnings Focus and Crowd Sourced Sentiment Review for Pieris Pharmaceuticals Inc (NASDAQ:PIRS) - TGP
07/19/16 05:38 AMPieris Pharmaceuticals Incorporated (NASDAQ:PIRS) Sellers Covered 15.84% of Their Shorts - Consumer Eagle
07/15/16 04:53 PMWoodward, Inc. (NASDAQ:WWD) Fell -0.32%: Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), Nippon Telegraph and ... - KC Register
07/15/16 10:58 AMTrading Performance and Target Watch for Pieris Pharmaceuticals Inc (NASDAQ:PIRS) - Press Telegraph
07/15/16 10:58 AMAnalyst Target and Average Rating Watch: Pieris Pharmaceuticals Inc (NASDAQ:PIRS) - Press Telegraph
07/15/16 10:58 AMPieris Pharmaceuticals Inc (NASDAQ:PIRS) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/11/16 05:50 PMPieris Pharmaceuticals Inc Stock Momentum at Critical Inflection Point - CML News
07/11/16 05:50 PMStock Rating Watch and Earnings Insight for Pieris Pharmaceuticals Inc (NASDAQ:PIRS) - Press Telegraph
07/08/16 05:51 PMIncreased Volatility on Shares of: Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) - Engelwood Daily
07/08/16 05:51 PMCan Pieris Pharmaceuticals Inc (NASDAQ:PIRS) Improve on the Earnings Front? - Engelwood Daily
07/08/16 05:51 PMCompany Stock Focus for Pieris Pharmaceuticals Inc (NASDAQ:PIRS): Which Way Will Shares Head? - Press Telegraph
07/08/16 05:51 PMBroker Outlook For Pieris Pharmaceuticals, Inc. (PIRS) - Fiscal Standard
07/06/16 10:29 AMNew Broker Ratings For Pieris Pharmaceuticals, Inc. (PIRS) - FTSE News
07/05/16 05:36 PMPieris Pharmaceuticals Inc (NASDAQ:PIRS) Stock Update: Check on Ratings and Target Price - Telanagana Press
07/02/16 08:36 AMPieris Pharmaceuticals Incorporated (NASDAQ:PIRS) Shorted Shares Decreased By 15.84% - Engelwood Daily
07/01/16 08:36 AMWatching Stock Volatility for: Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) - Engelwood Daily
07/01/16 08:36 AMUpdate on Stock Volatility for: Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) - Engelwood Daily
07/01/16 08:36 AMHow Analysts Rated Pieris Pharmaceuticals Inc (NASDAQ:PIRS) Last Week? - Engelwood Daily
07/01/16 07:49 AMPIERIS PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to -
06/29/16 08:38 AMPieris Pharmaceuticals Inc (NASDAQ:PIRS) Company Rating and Target Watch - Telanagana Press
06/27/16 09:59 AMShare Update and Earnings Review for Pieris Pharmaceuticals Inc (NASDAQ:PIRS) - Press Telegraph
06/24/16 05:54 PMHow Many Pieris Pharmaceuticals Inc (NASDAQ:PIRS)'s Analysts Are Bullish? - Press Telegraph
06/24/16 08:27 AMPieris Pharmaceuticals Incorporated (NASDAQ:PIRS) Short Interest Increased By 18.12% - Press Telegraph
06/24/16 08:27 AMCovering the Bases on Pieris Pharmaceuticals Inc (NASDAQ:PIRS): Where is the Stock Going? - Press Telegraph
06/24/16 08:27 AMPieris Pharmaceuticals, Inc. (PIRS) Current Analyst Ratings - Fiscal Standard
06/24/16 08:27 AMPieris Pharmaceuticals Inc (NASDAQ:PIRS) Earnings Glance and Target Price Review - Engelwood Daily
06/23/16 08:30 AMEquity Research and Technical Review on Pieris Pharmaceuticals Inc (NASDAQ:PIRS) - Press Telegraph
06/22/16 05:48 PMVeriFone Systems, Inc. (NYSE:PAY) Declined -1.38%: Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), American Water ... - KC Register
06/14/16 06:59 AMPieris Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences - [Marketwired] - Pieris Pharmaceuticals, Inc. , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer and other diseases, announced today ...
06/09/16 04:23 PMPIERIS PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events -
06/08/16 06:15 PMPieris Pharmaceuticals Announces Closing of $16.5 Million Private Placement
06/08/16 04:02 PMPIERIS PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -
06/04/16 08:45 AMPieris Pharmaceuticals Incorporated (NASDAQ:PIRS) Short Interest Decreased By 12.32% - HNN
06/03/16 08:44 AMShare Rating Focus on Pieris Pharmaceuticals Inc (NASDAQ:PIRS) - HNN - Share Rating Focus on Pieris Pharmaceuticals Inc (NASDAQ:PIRS)HNNThis stock research may entail following what professional equity analysts think about the company. Presently, Wall Street analysts have given a consensus stock rating of 1 on shares of Pieris Pharmaceuticals Inc (NASDAQ:PIRS). Covering analysts will ...and more »
06/03/16 08:00 AMPieris Pharmaceuticals Announces $16.5 Million Private Placement - [Marketwired] - Pieris Pharmaceuticals, Inc. announced today that it entered into a securities purchase agreement for a private placement with a select group of institutional investors, including lead investor BVF Partners ...
06/02/16 06:15 PMPieris Pharmaceuticals Inc (NASDAQ:PIRS) Stock Update & Estimates - Stock Tick Tock - Pieris Pharmaceuticals Inc (NASDAQ:PIRS) Stock Update & EstimatesStock Tick TockThe consensus on Wall Street is expecting Pieris Pharmaceuticals Inc (NASDAQ:PIRS) to post earnings of $-0.14 per share when the firm next reports it's fiscal quarterly results. According to the latest information available the report will likely be ...and more »
06/02/16 08:49 AMTarget Price and Stock Performance Rundown for Pieris Pharmaceuticals Inc (NASDAQ:PIRS) - HNN - Target Price and Stock Performance Rundown for Pieris Pharmaceuticals Inc (NASDAQ:PIRS)HNNDuring the latest trading session, Pieris Pharmaceuticals Inc (NASDAQ:PIRS) shares traded +1.05%. Monitoring the stock price relative to moving averages may offer enhanced perspective on stock performance. After a recent check, shares have been seen ...and more »
06/01/16 02:22 PMPieris Pharmaceuticals, Inc. :PIRS-US: Earnings Analysis: Q1, 2016 By the Numbers : June 1, 2016 -
05/30/16 06:23 PMPerformance at a Glance on Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) - HNN - Performance at a Glance on Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS)HNNWhen speculating how a given stock will perform in the future, it is important to look at how it has performed in the past. Today we will examine how Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS)'s stock has performed at various points in its past ...and more »
05/30/16 06:23 PMNext Weeks Broker Price Targets For Pieris Pharmaceuticals, Inc. (PIRS) - Share Trading News - Next Weeks Broker Price Targets For Pieris Pharmaceuticals, Inc. (PIRS)Share Trading News08/12/2015 – JMP Securities began new coverage on Pieris Pharmaceuticals, Inc. giving the company a “market outperform” rating. They now have a USD 10 price target on the stock. Pieris Pharmaceuticals, Inc. has a 50 day moving average of 1.99 and a ...Pieris Pharmaceuticals Incorporated (NASDAQ:PIRS) Sellers Covered 12.32% of Their ShortsFranklin Independentall 2 news articles »
05/20/16 01:41 PMAnalyst Rating Check on Pieris Pharmaceuticals Inc (NASDAQ:PIRS) - Wall Street Hints and News - Analyst Rating Check on Pieris Pharmaceuticals Inc (NASDAQ:PIRS)Wall Street Hints and NewsThis research may involve tracking what professional equity analysts think about the company. Currently, sell-side analysts have provided a consensus stock rating of 1 on shares of Pieris Pharmaceuticals Inc (NASDAQ:PIRS). Analysts that cover the ...and more »
03/28/16 10:50 AMPieris Pharmaceuticals, Inc. :PIRS-US: Earnings Analysis: Q4, 2015 By the Numbers -

Social

About Pieris Pharmaceuticals

Pieris Pharmaceuticals logoPieris Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids. It is focused on developing three drug candidates, which include PRS-080, PRS-060 and PRS-300 series. Its PRS-080 is an Anticalin drug candidate targeting hepcidin. The Company's second Anticalin drug candidate, PRS-060, binds to the IL-4 receptor alpha-chain (IL-4RA), thereby inhibiting the actions of IL-4 and IL-13, two cytokines known to be mediators in the inflammatory cascade that causes asthma and other inflammatory diseases. PRS-343 is an Anticalin-based drug candidate.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: PIRS
  • CUSIP:
Key Metrics:
  • Previous Close: $1.76
  • 50 Day Moving Average: $1.68
  • 200 Day Moving Average: $1.81
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $70.11M
  • Beta: 1.58
  • Current Year EPS Consensus Estimate: $-0.5 EPS
  • Next Year EPS Consensus Estimate: $-0.48 EPS
Additional Links:
Pieris Pharmaceuticals (NASDAQ:PIRS) Chart for Saturday, July, 30, 2016